What is LACI-3?

LACI-3 is a research study looking at how we can better protect the brain after a lacunar stroke, a type of stroke that affects around 35,000 people each year in the UK. These strokes happen when small blood vessels deep in the brain become damaged and can no longer deliver oxygen and nutrients properly. This condition, known as small vessel disease, increases the risk of another stroke happening, and can also lead to problems with thinking, balance, walking, and even dementia. Currently, there are no treatments that directly target the small blood vessels in the brain. 

We plan to test if two drugs called cilostazol and isosorbide mononitrate can prevent problems with thinking, memory, more strokes and mobility, and dementia, which can occur after a lacunar stroke.

Both drugs are already widely used to treat other health problems, but this is the first time they’re being tested to treat small vessel disease in the brain.

If you would like to learn more about small vessel disease, click here.

Alongside testing new treatments, LACI-3 ensures all participants receive the best available care based on current clinical guidelines. While LACI-3 is testing two promising drugs, it’s essential to remember that standard medical treatment remains the foundation of care for people with small vessel disease.

In addition to medical treatment, making positive lifestyle changes — such as stopping smoking, staying active, eating well, and keeping blood pressure under control — can also help protect the small blood vessels in the brain. These steps support brain health, improve blood flow, and reduce the risk of further strokes, memory and thinking problems, and dementia.

Click here to learn more about resources and support available for people experiencing cerebral small vessel disease, stroke, and other age-related brain conditions.